Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 14/20 | 0.62 |
| ▸ | PDE4B | Q07343 | 14/20 | 0.62 |
| ▸ | PDE4C | Q08493 | 14/20 | 0.62 |
| ▸ | PDE4D | Q08499 | 14/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 11/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8363167 | 0.87 | PDE4A (0.68) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL4031519 | 0.83 | PDE4A (0.58) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL6181324 | 0.83 | PDE4A (0.59) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| Alcohol SCHEMBL4026942 | 0.81 | PDE4A (0.58) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL4037063 | 0.80 | PDE4A (0.66) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL6983382 | 0.80 | PDE4A (0.47) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL4036955 | 0.79 | PDE4A (0.53) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL4039795 | 0.78 | PDE4A (0.68) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL4043959 | 0.77 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL4041660 | 0.77 | PDE4A (0.57) | PDE4APDE4BPDE4CPDE4DCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1363635-B1 | SUBSTITUTED 8-ARYLQUINOLINE PHOSPHODIESTERASE-4 INHIBITORS | MERCK & CO INC (US) | 2009-04-15 | — | — | EP | disclosed |
| US-6740666-B2 | FOR THERAPY OF ASTHMA, CHRONIC BRONCHITIS, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, EOSINOPHILIC GRANULOMA, PSORIASIS; SEPTIC SHOCK, ULCERATIVE COLITIS, CROHN'S DISEASE, REPERFUSION INJURY OF THE MYOCARDIUM AND BRAIN, INFLAMMATION | MERCK & CO., INC. | 2004-05-25 | — | — | US | disclosed |
| EP-1363635-A1 | SUBSTITUTED 8-ARYLQUINOLINE PHOSPHODIESTERASE-4 INHIBITORS | Merck & Co., Inc. (US) | 2003-11-26 | — | — | EP | disclosed |
| US-20020143032-A1 | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2002-10-03 | — | — | US | disclosed |
| EP-1244628-A1 | SUBSTITUTED 8-ARYLQUINOLINE PHOSPHODIESTERASE-4 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 2002-10-02 | — | — | EP | disclosed |
| WO-2002069970-A1 | SUBSTITUTED 8-ARYLQUINOLINE PHOSPHODIESTERASE-4 INHIBITORS | MERCK & CO., INC. (US) | 2002-09-12 | — | — | WO | disclosed |
| US-20020103226-A1 | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2002-08-01 | — | — | US | disclosed |
| US-6410563-B1 | RESPIRATORY SYSTEM DISORDERS; ANTIARTHRITIC AGENTS | MERCK FROSST CANADA & CO. (CA) | 2002-06-25 | — | — | US | disclosed |
| WO-2001046151-A1 | SUBSTITUTED 8-ARYLQUINOLINE PHOSPHODIESTERASE-4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103226-A1 | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors | PDE4A, PDE4B, PDE4C | PDE4A 1/4885PDE4B 2/4885PDE4C 3/4885 |
| US-20020143032-A1 | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors | PDE4A, PDE4B, PDE12 | PDE4A 1/4885PDE4B 2/4885PDE4C 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.